BiotechTube
P2D Bioscience

P2D Bioscience

San Diego, United States· Est.
p2dinc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Founded in 2016, P2D Bioscience is a private, preclinical-stage biotech developing novel therapeutics for CNS inflammatory disorders. Its pipeline features two distinct drug candidate classes: orally active isoindoline TNFα inhibitors for FTD and AD, and benztropine-analog dopamine transporter (DAT) inhibitors for ADHD. The company's strategy is to advance candidates through early clinical proof-of-concept before seeking partnerships for later-stage development and commercialization. P2D operates as a virtual or asset-centric company, leveraging experienced management and a focused platform to de-risk programs for potential partners.

Frontotemporal DementiaAlzheimer's diseaseAttention Deficit/Hyperactivity Disorder

Technology Platform

Targeted Phenotypic Screening combined with transgenic preclinical models of neurodegenerative diseases to accelerate drug discovery and candidate selection.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive, underserved markets for Alzheimer's and Frontotemporal Dementia, with no approved disease-modifying therapies for FTD, present a significant opportunity.
Successfully developing an orally bioavailable, CNS-penetrant TNFα inhibitor would address a key therapeutic gap in neuroinflammation.
The ADHD program offers a chance to develop a novel non-stimulant mechanism in a large, established market.

Risk Factors

High scientific risk that inhibiting TNFα in the CNS will modify disease progression in FTD/AD, and that preclinical findings will not translate clinically.
Significant financing risk as a private, preclinical company needing capital for expensive development.
Intense competition from larger players in both neurodegeneration and ADHD.

Competitive Landscape

In neurodegeneration, P2D competes with large pharma (Biogen, Eli Lilly, Roche) and numerous biotechs targeting neuroinflammation via various pathways (TREM2, microglia). In ADHD, it faces entrenched generic stimulants and branded drugs from companies like Takeda and Supernus. P2D's differentiation hinges on its specific mechanism (oral CNS TNFα inhibition) and its targeted phenotypic screening platform.

More companies in Small Molecule Drugs →More companies in United States →